All In Biotech

Drug Trial Radar · NCT01402986

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma

Last checked: Nov 20, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 689 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

689

Actual

Start

Aug 2011

Primary completion

Jun 2013

Study completion Feb 2014

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.

Conditions

  • Asthma

Interventions

  • Placebo Q2WOther

    Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

  • Tralokinumab 300 mg, Q2WBiological

    Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.

  • Placebo, Q2/4WOther

    Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.

  • Tralokinumab 300 mg, Q2/4WBiological

    Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate (AER)Time frame: Week 1 up to Week 53

Locations

89 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Rancho Mirage, California

  • Research Site

    Centennial, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Cocoa, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Albany, Georgia

  • Research Site

    Fargo, North Dakota

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Upland, Pennsylvania

  • Research Site

    Killeen, Texas

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Monte Grande, Argentina

  • Research Site

    Ranelagh, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Quillota, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Valparaíso, Chile

  • Research Site

    Viña del Mar, Chile

  • Research Site

    Jindřichův Hradec, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Rokycany, Czechia

  • Research Site

    Marseille, France

  • Research Site

    Montpellier, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Perpignan, France

  • Research Site

    Pessac, France

  • Research Site

    Strasbourg, France

  • Research Site

    Berlin, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Lübeck, Germany

  • Research Site

    Mainz, Germany

  • Research Site

    Chūōku, Japan

  • Research Site

    Fujisawa-shi, Japan

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.